Novo Nordisk | NVO - Current Assets


Novo Nordisk reported DKK25.71B in Current Assets for its fiscal quarter ending in June of 2025.





Current Assets Change Date
ANI Pharmaceuticals USD 698.4M 95.77M Sep/2025
Aurora Cannabis CAD 423.84M 41.46M Sep/2025
Bausch Health Companies USD 6.16B 92M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Canopy Growth CAD 445.82M 142.46M Sep/2025
Corcept Therapeutics USD 541.13M 98.02M Sep/2025
Drreddys Laboratories INR 3.31B 164.26M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Novo Nordisk DKK 172.45B 9.43B Dec/2025
Novo Nordisk DKK 25.71B 148.69B Jun/2025
Pacira USD 562.75M 182.86M Sep/2025
Perrigo USD 2.88B 264.2M Sep/2025
Phibro Animal Health USD 862.18M 26.39M Dec/2025
Prestige Brands USD 433.43M 63.98M Dec/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Supernus Pharmaceuticals USD 593.89M 144.98M Sep/2025
Zoetis USD 6.77B 185M Dec/2025